Cost-effectiveness analysis of a strategy to delay progression to dialysis and death among chronic kidney disease patients in Lima, Peru

Author:

Saldarriaga E. M.,Bravo-Zúñiga J.,Hurtado-Roca Y.,Suarez V.ORCID

Abstract

Abstract Background The Renal Health Program (RHP) was implemented in 2013 as a secondary prevention strategy to reduce the incidence of patients initiating dialysis and overall mortality. A previous study found that adherent patients have 58% protection against progression to dialysis compared to non-adherent. The main objective of the study was to estimate the lifetime economic and health consequences of the RHP intervention to determine its cost-effectiveness in comparison with usual care. Methods We use a Markov model of three health stages to simulate disease progression among chronic kidney disease patients in Lima, Peru. The simulation time-horizon was 30 years to capture the lifetime cost and health consequences comparing the RHP to usual care. Costs were estimated from the payer perspective using institutional data. Health outcomes included years lived free of dialysis (YL) and quality adjusted life years (QALY). We conducted a probabilistic sensitivity analysis (PSA) to assess the robustness of our estimates against parameter uncertainty. Results We found that the RHP was dominant—cost-saving and more effective—compared to usual care. The RHP was 783USD cheaper than the standard of care and created 0.04 additional QALYs, per person. The Incremental Cost-Effectiveness Ratio (ICER) showed a cost per QALY gained of $21,660USD. In the PSA the RHP was dominant in 996 out of 1000 evaluated scenarios. Conclusions The RHP was cheaper than the standard of care and more effective due to a reduction in the incidence of patients progressing to dialysis, which is a very expensive treatment and many times inaccessible. We aim these results to help in the decision-making process of scaling-up and investment of similar strategies in Peru. Our results help to increase the evidence in Latin America where there is a lack of information in the long-term consequences of clinical-management-based prevention strategies for CKD patients.

Funder

Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI), EsSalud. Lima, Perú

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Reference30 articles.

1. Francis ER, et al. Burden of chronic kidney disease in resource-limited settings from Peru: a population-based study. BMC Nephrol. 2015;16:114.

2. Loza-Munarriz C, Ramos-Muñoz W. Situation analysis of the chronic kidney disease in Peru. 2016. https://www.spn.pe/archivos/ANALISIS%20DE%20LA%20SITUACION%20DE%20LA%20ENFERMEDAD%20RENAL%20CRONICA%20EN%20%20EL%20PERU%20(1).pdf.

3. Dirección General de Epidemiología—DGE. Carga de Enfermedad en el Perú. Estimación de los años de vida saludables perdidos. 2014. http://www.dge.gob.pe/portal/docs/tools/Cargaenfermedad2012.pdf. Accessed 19 Jan 2018

4. Mushi L, Marschall P, Fleßa S. The cost of dialysis in low and middle-income countries: a systematic review. BMC Health Serv Res. 2015. https://doi.org/10.1186/s12913-015-1166-8.

5. Herrera-Añazco P, Benites-Zapata VA, León-Yurivilca I, Huarcaya-Cotaquispe R, Silveira-Chau M. Chronic kidney disease in Peru: a challenge for a country with an emerging economy. J Bras Nefrol. 2015;37(4):507-508. https://doi.org/10.5935/0101-2800.20150081.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3